Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 9:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 5,144 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Acquired Immunodeficiency Syndromes Clear all
Completed Phase 3 Interventional Results available

Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)

NCT04223791
View directory record Official record
Conditions
HIV Infection
Interventions
DOR/ISL, BIC/FTC/TAF, Placebo to BIC/FTC/TAF, Placebo to FDC DOR/ISL
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
28
States / cities
Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 21, 2026, 9:44 AM EDT
Completed Not applicable Interventional

A Pilot Study of 566C80 for the Salvage Treatment of Toxoplasmic Encephalitis in Patients Infected With the Human Immunodeficiency Virus (HIV) Who Have Failed or Are Intolerant of Pyrimethamine-Sulfadiazine

NCT00001994
View directory record Official record
Conditions
Toxoplasmosis, Cerebral, HIV Infections
Interventions
Atovaquone
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
18
States / cities
Los Angeles, California • Oakland, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 21, 2026, 9:44 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Northwest Therapies Trauma Psilocybin Study Compassionate Use Study

NCT05042466
View directory record Official record
Conditions
Trauma, Nervous System
Interventions
Trauma
Drug
Lead sponsor
NWTraumatherapies
Network
Eligibility
21 Years to 99 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Bozeman, Montana
Source: ClinicalTrials.gov public record
Updated Nov 16, 2022 · Synced Oct 21, 2026, 9:44 AM EDT
Completed Phase 1 Interventional

Evaluation of the Safety and Tolerance of Immunotherapy With Autologous, Ex-Vivo Expanded, HIV-Specific Cytotoxic T-Cells in HIV-Infected Patients With CD4+ Counts Between 100-400/mm3

NCT00000756
View directory record Official record
Conditions
HIV Infections
Interventions
Lymphocytes, Activated
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2002
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 21, 2026, 9:44 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Clinical Trial to Evaluate the Safety and Immunogenicity of Synthetic DNAs Encoding a Native-like HIV Env Trimer and Interleukin-12 (INO-6160), Alone or in a Prime-boost Regimen With 3M-052-AF + Alum Adjuvanted VRC HIV Env Trimer 4571 in Adult Participants Without HIV

NCT05828095
View directory record Official record
Conditions
HIV-1-infection
Interventions
INO-6160, 2 mg, Trimer-4571 / 100 mcg 3M-052-AF (5 mcg) + Alum (500 mcg)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
3
States / cities
New York, New York • Philadelphia, Pennsylvania • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Oct 21, 2026, 9:44 AM EDT
Not listed Not applicable Interventional

Effects of Home Visits on Medication Adherence in Children and Youth With HIV

NCT00006439
View directory record Official record
Conditions
HIV Infections
Interventions
Counseling in the home
Behavioral
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
0 Years to 24 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 21, 2026, 9:44 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Simplified Consent for HIV Vaccine Trials

NCT00105339
View directory record Official record
Conditions
Adolescent Behavior
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
15 Years to 19 Years
Enrollment
255 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2004
U.S. locations
3
States / cities
Los Angeles, California • Fort Lauderdale, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 1, 2017 · Synced Oct 21, 2026, 9:44 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Online Network Intervention to Increase HIV Pre-exposure Prophylaxis Intention

NCT04771312
View directory record Official record
Conditions
Behavior, Health
Interventions
Mobile app information-only intervention, Mobile app social support network intervention
Behavioral
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 35 Years · Male only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Oct 1, 2021 · Synced Oct 21, 2026, 9:44 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Inflammation and Cardiovascular Health in Women

NCT04224181
View directory record Official record
Conditions
HIV/AIDS, Myocardial Infarction
Interventions
Cardiac PET, 99mTc-tilmanocept SPECT/CT, Contrast Enhanced Coronary and Aortic Computed Tomography Angiography
Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 79 Years · Female only
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Oct 21, 2026, 9:44 AM EDT
Completed Phase 1 Interventional

Altretamine and Etoposide in Treating Patients With HIV-Related Cancer

NCT00002936
View directory record Official record
Conditions
Lymphoma, Sarcoma
Interventions
altretamine, etoposide
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Oct 21, 2026, 9:44 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)

NCT05996471
View directory record Official record
Conditions
HIV Infections
Interventions
VH3810109, Cabotegravir, Standard of care (SOC), rHuPH20
Biological · Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 70 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
43
States / cities
Birmingham, Alabama • Bakersfield, California • Los Angeles, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 21, 2026, 9:44 AM EDT
Completed Phase 1 Interventional

Open Label Phase I Study To Evaluate the Safety of Combination Therapy With AZT and Interferon-Beta in Patients With AIDS Related Kaposi's Sarcoma

NCT00000695
View directory record Official record
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
Interferon beta-1b, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1991
U.S. locations
4
States / cities
Los Angeles, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 21, 2026, 9:44 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Pilot Intervention to Improve Coping With Discrimination and Adherence Among HIV-Positive Latino MSM

NCT03432819
View directory record Official record
Conditions
HIV
Interventions
Siempre Seguiré
Behavioral
Lead sponsor
RAND
Other
Eligibility
18 Years and older · Male only
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 29, 2023 · Synced Oct 21, 2026, 9:44 AM EDT
Completed Phase 2 Interventional Results available

Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting (LA) Cabotegravir (CAB) Plus LA Rilpivirine (RPV), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV)-Positive Participants From the LATTE Study

NCT03639311
View directory record Official record
Conditions
HIV Infections
Interventions
CAB LA, RPV LA, RPV, DTG
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
25
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2024 · Synced Oct 21, 2026, 9:44 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Motiv82Change: an HIV Prevention Study for Young Latino Men

NCT00877695
View directory record Official record
Conditions
HIV Infections
Interventions
Entre Culturas: Navigating Culture, Identity, and HIV Risk
Behavioral
Lead sponsor
Nova Southeastern University
Other
Eligibility
18 Years to 29 Years · Male only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 4, 2013 · Synced Oct 21, 2026, 9:44 AM EDT
Completed Phase 1 Interventional

Infrared Coagulation in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia

NCT00066430
View directory record Official record
Conditions
Anal Cancer, Precancerous Condition
Interventions
infrared photocoagulation therapy, Infrared Coagulator
Procedure · Device
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
2
States / cities
San Francisco, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 17, 2014 · Synced Oct 21, 2026, 9:44 AM EDT
Active, not recruiting Phase 3 Interventional

Optimizing Tobacco Use Treatment for PLWHA

NCT04176172
View directory record Official record
Conditions
HIV/AIDS, Nicotine Dependence
Interventions
Varenicline, Nicotine patch, Standard treatment, Standard treatment + Managed Problem Solving (MAPS) adherence intervention
Drug · Behavioral
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
2
States / cities
Chicago, Illinois • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 21, 2026, 9:44 AM EDT
Completed Phase 2 Interventional Results available

Effect of Intermittent Aldesleukin Treatment With or Without Anti-HIV Drugs in HIV Infected People

NCT00110812
View directory record Official record
Conditions
HIV Infections
Interventions
IL-2
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
11
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Bethesda, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 21, 2026, 9:44 AM EDT
Recruiting Not applicable Interventional

Strategies to AchieVe Viral Suppression for Youth With HIV

NCT06886971
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV) Infection
Interventions
The SAVVY intervention includes CHOICE counseling and shared decision-making regarding ART preference (informed by the evidence-based HIV-ASSIST) and facilitating LA-ART access
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
12 Years to 30 Years
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 21, 2026, 9:44 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Repeat Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects

NCT02289495
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
GSK2838232, Placebo, Ritonavir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 21, 2026, 9:44 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

ID & Testing in Male Partners

NCT01033812
View directory record Official record
Conditions
HIV
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 24 Years
Enrollment
177 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
3
States / cities
Miami, Florida • Chicago, Illinois • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Oct 21, 2026, 9:44 AM EDT
Completed No phase listed Observational

Seek, Test, Treat, Retain: An Integrated Jail-Prison-Community Model for Illinois

NCT01852877
View directory record Official record
Conditions
HIV Infections
Interventions
Corrections case management
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
784 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 15, 2019 · Synced Oct 21, 2026, 9:44 AM EDT
Completed Not applicable Interventional

A Mobile Gaming App to Improve ART Adherence for Youth

NCT03760211
View directory record Official record
Conditions
Medication Adherence, HIV/AIDS
Interventions
Multilevel Gaming Adherence Intervention, Treatment as Usual +
Behavioral
Lead sponsor
Rhode Island Hospital
Other
Eligibility
15 Years to 30 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
4
States / cities
Atlanta, Georgia • Boston, Massachusetts • Jackson, Mississippi + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2025 · Synced Oct 21, 2026, 9:44 AM EDT
Completed Phase 4 Interventional Results available

Mesalamine to Reduce T Cell Activation in HIV Infection

NCT01090102
View directory record Official record
Conditions
HIV Infections, Sexually Transmitted Diseases, Immune System Diseases, Lentivirus Infections, Acquired Immunodeficiency Syndrome
Interventions
Mesalamine (5-aminosalicylic acid, Apriso), Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2014 · Synced Oct 21, 2026, 9:44 AM EDT